Investors
Cell Tech is a clinical stage biotech company advancing the first ever FDA and Health Canada-approved stem cell technology to market.
Stem Cell Innovation
Regenerative medicine market is expected to grow to USD $150B by 2028 with 23.5% CARG and be an active investment area for pharmaceutical companies, including Astellas, J&J and Fujifilm.
Market Outlook
Osteoarthritis (OA) and Degenerative Disk Disease are two common chronic diseases affecting millions of people globally with devastating medical and economic impacts.
Chronic Pain Solutions
Cell Tech’s unique position is based on our proprietary technology with a solid moat of 6 patents and multiple publications. Our stem cells are the only ones able to specifically target and treat arthritis. Human studies validating the technology showed a breakthrough success.
Unique Position
Cell Tech is launching a late-stage trial and eyeing Exclusive Market Authorization (EMA) in Canada, granting it as the exclusive stem cell provider in Canada for 100% market share for the next 8 years. It also has the first FDA approved stem cells in the US for Osteoarthritis,